Biological and therapeutic implications of the cancer-related germline mutation landscape in lung cancer.

Autor:	Panagiotou E; Third Department of Internal Medicine, Sotiria General Hospital for Chest Diseases, National and Kapodistrian University of Athens, Athens, Greece., Vathiotis IA; Third Department of Internal Medicine, Sotiria General Hospital for Chest Diseases, National and Kapodistrian University of Athens, Athens, Greece. Electronic address: johnvathiotis1@gmail.com., Makrythanasis P; Laboratory of Medical Genetics, Medical School, National and Kapodistrian University of Athens, Athens, Greece; Department of Genetic Medicine and Development, Medical School, University of Geneva, Geneva, Switzerland; Biomedical Research Foundation of the Academy of Athens, Athens, Greece., Hirsch F; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Sen T; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: triparna.sen@mssm.edu., Syrigos K; Third Department of Internal Medicine, Sotiria General Hospital for Chest Diseases, National and Kapodistrian University of Athens, Athens, Greece.
Jazyk:	angličtina
Zdroj:	The Lancet. Respiratory medicine [Lancet Respir Med] 2024 Dec; Vol. 12 (12), pp. 997-1005. Date of Electronic Publication: 2024 Jun 14.
DOI:	10.1016/S2213-2600(24)00124-3
Abstrakt:	Although smoking is the primary cause of lung cancer, only about 15% of lifelong smokers develop the disease. Moreover, a substantial proportion of lung cancer cases occur in never-smokers, highlighting the potential role of inherited genetic factors in the cause of lung cancer. Lung cancer is significantly more common among those with a positive family history, especially for early-onset disease. Therefore, the presence of pathogenic germline variants might act synergistically with environmental factors. The incorporation of next-generation sequencing in routine clinical practice has led to the identification of cancer-predisposing mutations in an increasing proportion of patients with lung cancer. This Review summarises the landscape of germline susceptibility in lung cancer and highlights the importance of germline testing in patients diagnosed with the disease, which has the potential to identify individuals at risk, with implications for tailored therapeutic approaches and successful prevention through genetic counselling and screening. Competing Interests: Declaration of interests FH has a patent through the University of Colorado for EGFR protein and EGFR copy number as predictive biomarkers for EGFR-directed therapies (no financial provision); has participated in scientific advisory boards for Amgen, AstraZeneca, Novartis, Regeneron, Genzyme, Sanofi, Daiichi, Novocure, Novohost, Next Cure, G1-Therapeutics, and Merus; was CEO for the International Association for the Study of Lung Cancer 2013–2018; and is currently chair of the Molecular Subcommitte (unpaid) and co-chair of the Southwest Oncology Group Lung Cancer Translational Committee (unpaid). TS is co-investor for Synergistic Liposomal Formulation for the Treatment of Cancer (no financial provision) and has received grant funding from Jazz Pharmaceuticals. All other authors declare no competing interests. (Copyright © 2024 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu